Cardiac and renal sympathetic nerve activation in early-stage HFpEF: insights from 131I-MIBG imaging study
The International Journal of Cardiovascular Imaging · 2025
DOI: 10.1007/s10554-025-03586-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift The International Journal of Cardiovascular Imaging, 2025. Verfasst von Meijing Shi und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Graduate, Hebei Medical University, Shijiazhuang, 050031, Hebei Province, China. Hauptthemen laut MEDLINE: 3-Iodobenzylguanidine, Sympathetic Nervous System, Radiopharmaceuticals, Kidney. Die Arbeit nennt 28 Literaturangaben.
Abstract (Originalsprache)
While sympathetic overactivity is a well-established driver of disease progression in heart failure with reduced ejection fraction, its role in early-stage heart failure with preserved ejection fraction (HFpEF) remains unclear. In particular, renal sympathetic activity-an important contributor to neurohormonal dysregulation-has not been systematically evaluated in HFpEF. Early-stage HFpEF refers to patients who present with mild symptoms, only modest elevations in B-type natriuretic peptide (BNP), and invasively confirmed elevated left ventricular end-diastolic pressure (LVEDP) but without overt structural remodeling or severe congestion. We conducted a single-center retrospective randomized controlled study including 121 patients with early-stage HFpEF and 44 matched controls. All participants underwent 131I-metaiodobenzylguanidine (131I-MIBG) scintigraphy to quantify sympathetic nerve activity in the heart and kidneys. Uptake ratios (15 min and 4 h heart-to-mediastinum [H/Ma] and kidney-to-posterior mediastinum [K/Mp]) and washout rates (Heart Washout Rate [HWR] and Kidney washout Rate [KWR]) were calculated. Correlations with these MIBG parameters and left ventricular end-diastolic pressure (LVEDP) were analyzed. HFpEF patients showed significantly higher cardiac H/Ma and renal K/Mp ratios, and lower HWR and KWR compared with controls (all P < 0.001). In the HFpEF group, both 4-h H/Ma and 4-h K/Mp ratios were positively correlated with LVEDP, while HWR and KWR were inversely correlated with these indices (all P < 0.01). Early-stage HFpEF patients show increased cardiac and renal sympathetic activity, highlighting the renal sympathetic nervous system as a potential therapeutic target and suggesting 131I-MIBG scintigraphy as a promising tool for risk stratification and early intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Graduate, Hebei Medical University, Shijiazhuang, 050031, Hebei Province, China.
- Cangzhou Medical College, Changzhou, 061000, Hebei Province, China.
- Department of Radiology and Nuclear Medicine, First Affiliated Hospital of Hebei Medical University, Hebei Province, 050031, China.
- Department of Cardiology, Heart Center, First Affiliated Hospital of Hebei Medical University, Shijiazhuang, 050031, Hebei Province, China.
- Department of Cardiology, Heart Center, First Affiliated Hospital of Hebei Medical University, Shijiazhuang, 050031, Hebei Province, China. liuchao@hebmu.edu.cn.
Zitieren
APA
Shi, M., Yang, Z., Yin, P., Zhao, H., Li, L., Zhen, Y., Zhao, Q., & Liu, C. (2025). Cardiac and renal sympathetic nerve activation in early-stage HFpEF: insights from 131I-MIBG imaging study. The International Journal of Cardiovascular Imaging. https://doi.org/10.1007/s10554-025-03586-5
Vancouver
Shi M, Yang Z, Yin P, Zhao H, Li L, Zhen Y, et al. Cardiac and renal sympathetic nerve activation in early-stage HFpEF: insights from 131I-MIBG imaging study. The International Journal of Cardiovascular Imaging. 2025. doi:10.1007/s10554-025-03586-5
BibTeX
@article{Shi2025,
author = {Shi, Meijing and Yang, Zhiqiang and Yin, Pei and Zhao, Huayi and Li, Lizhuo and Zhen, Yuzhi and Zhao, Qingzhen and Liu, Chao},
title = {Cardiac and renal sympathetic nerve activation in early-stage HFpEF: insights from 131I-MIBG imaging study},
journal = {The International Journal of Cardiovascular Imaging},
year = {2025},
doi = {10.1007/s10554-025-03586-5}
}
EUVIMED